Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease

Jane H. Buckner and Carla J. Greenbaum
J Immunol November 1, 2017, 199 (9) 3011-3013; DOI: https://doi.org/10.4049/jimmunol.1701299
Jane H. Buckner
*Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jane H. Buckner
Carla J. Greenbaum
†Diabetes Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carla J. Greenbaum
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Although symptoms of diabetes were first written about in 1500 bc, the etiology of the disease was a mystery until Minkowski and von Mering found that the pancreas governs glucose control (1). This led to the discovery and use of insulin in 1922 (2), enabling the survival of children with diabetes. Himsworth (3) subsequently described two types of people with diabetes: those who were insulin resistant and those who were insulin sensitive. The clinically defined terms insulin-dependent and non–insulin-dependent diabetes mellitus (4, 5) gave way by 1997, respectively, to type 1 diabetes (T1D) as a disease caused by immune-mediated β cell destruction and type 2 diabetes (T2D) as primarily a disease of insulin resistance (6).

The featured articles by Bottazzo et al. (7) and MacCuish et al. (8) in 1974 were instrumental in developing our understanding that the immune system is involved in T1D, because autoantibodies directed at the pancreatic islet cell were found for the first time. Interestingly, these seminal articles identified the autoantibodies in individuals with immune diseases affecting multiple organs. In both articles, the pivotal aspect of the research design was the selection of individuals with diabetes and one or more additional organ-specific autoimmune diseases. Many of these individuals likely had autoimmune polyglandular syndrome 1 (APS1 or autoimmune polyendocrinopathy candidiasis ectodermal dystrophy), a clinical constellation classically manifested by adrenal insufficiency, hypoparathyroidism, and mucocutaneous candidiasis but also associated with vitiligo, pernicious anemia, and T1D. These symptoms are now known to be caused by heterozygous or homozygous mutations in AIRE, which codes for autoimmune regulator (9–11). AIRE deficiency or related genetic defects lead to a failure of central T cell tolerance and the development of tissue-specific autoantibodies and, ultimately, multiorgan disease. Recent studies show that individuals who lack AIRE develop somatically mutated autoantibodies of very high affinity for conformational epitopes (12). Such high-affinity Abs are more easily detected than lower-affinity Abs, and this may explain why Bottazzo et al. and MacCuish et al. were able to identify islet Abs in this cohort. The study of these rare individuals shed light on the role of autoimmunity in T1D.

The articles by Bottazzo et al. and MacCuish et al., together with evidence from animal models and pancreatic specimens, along with the observed association of diabetes with other autoimmune diseases, selected HLA class II genotypes, and increased risk in family members, also contributed to the concept that insulin-dependent diabetes mellitus was immune mediated (13). Today, the strong HLA class II association in humans and animal models supports the concept that T1D is predominantly T cell mediated, although as our understanding of immunology grows, it is becoming clear that multiple cell types participate in disease pathogenesis (14). Although there is no evidence that autoantibodies themselves are pathogenic, the identification of islet-specific Abs in these seminal articles also raises the question of whether B cells are pathogenic or secondary to the immune pathology. The role of B cells in T1D has been controversial because of the ability of T cells to transfer disease in the absence of B cells (15) and the observed development of T1D in an individual with B cell deficiency due to a BTK mutation (16). However, the majority of studies supports a role for B cells in diabetes (17); insulin-specific B cells have been shown to play a role in disease development in the NOD mouse model (18), and B cell–depletion therapy was efficacious in preserving endogenous insulin secretion in individuals with T1D (19).

Recognition of the role of autoimmunity in T1D led to the first clinical trials attempting to interrupt the destructive immune process. The immune suppressant cyclosporine was shown to alter the disease course in the early 1980s (20–22). However, this therapy was abandoned because of toxicity with chronic use. More recent clinical trials have targeted several immune pathways and mechanisms, including T and B cell activation and inflammatory cytokines, among others (23). There are now four immune therapies with different mechanisms of action that have reasonable safety profiles and that temporarily alter the disease course of T1D (19, 24–26). Indeed, the effects of immune therapy in T1D are not dissimilar to those seen in other autoimmune diseases.

The Bottazzo et al. and MacCuish et al. findings in 1974 led to refinements of their islet cell autoantibody (ICA) assay, more widespread testing, and a search for the Ags involved. In 1983, Jerry Palmer and colleagues (27) described the presence of insulin-specific Abs prior to treatment with insulin (which were thus “auto” Abs). Baekkeskov et al. (28) identified Abs to glutamic acid decarboxylase by 1990, Abs to protein tyrosine phosphatases (islet Ag 2/ICA512) were described in the mid-1990s (29), and Hutton’s team (30) identified autoantibodies to zinc transporter 8 in 2007. The latter four are described as biochemical Abs and can be reliably measured in radioimmunoassays because the target Ags are defined. In contrast, ICAs are still measured by detection of reactivity of test serum to cadaver pancreatic islets. This labor-intensive process remains in use in research studies because ICAs have additional, as yet unknown, Ag specificities beyond insulin, glutamic acid decarboxylase, islet Ag 2, and zinc transporter 8. Indeed, recent articles describing hybrid peptides (31, 32) and posttranslationally modified Ags (33) suggest the existence of additional autoantibody specificities.

Of critical importance, soon after the 1974 articles, the leaders in the field, including George Eisenbarth, joined together to cross-compare and validate Ab measurements. Ab testing, validation, and standardization continue to be conducted through the Diabetes Antibody Standardization Program, now under National Institute of Diabetes and Digestive and Kidney Diseases leadership, as new assays and variations of assays are described that are aimed to reduce blood volume and cost or increase sensitivity and specificity. Using these validated assays, more than 90% of individuals identified clinically with T1D can be shown to have one or more autoantibodies at the time of diagnosis.

Interestingly, Bottazzo et al.’s article included several subjects without diabetes who were ICA+, including one who subsequently developed diabetes. This presages what is arguably the most important impact of autoantibody measurements. The presence of islet autoantibodies in individuals prior to clinical diabetes diagnosis has allowed the study of disease progression and pathogenesis and the conduct of clinical trials to alter disease course. Research studies measure Abs in genetically at-risk populations identified by virtue of screening family members or testing for high-risk HLA class II genotypes. Over the past 30 years, such studies have refined our understanding of disease progression such that we now consider T1D as starting when two or more autoantibodies are present, because almost all of these individuals progress to clinically overt disease (34). Individuals with two or more autoantibodies have stage 1 diabetes if their glucose tolerance is normal, stage 2 diabetes if they have two or more autoantibodies and abnormal glucose tolerance, and stage 3 diabetes if they have clinically overt disease (35). Immune therapies are being tested in early stages of disease to prevent or delay progression to clinical onset.

Although the association of autoantibodies with clinically typical T1D is clear, the lines separating T1D and T2D are increasingly blurred. Thus, T2D involves β cell dysfunction and can occur in children, and some individuals with T2D have autoantibodies and islet T cell autoreactivity. Conversely, insulin resistance can be a component of T1D, and many people with long-standing T1D have evidence of residual β cell function; thus, immune-mediated β cell destruction is not always complete. Moreover, recent years have seen a revival of studies on the role that the β cell plays in its own demise. But, as first articulated by Bottazzo et al., whether β cell injury and death are from suicide or homicide, there is no question that the immune system is involved in the pathogenesis of disease.

Disclosures

The authors have no financial conflicts of interest.

Acknowledgments

The authors wish to acknowledge that Dr. Gian Franco Bottazzo died on September 15, 2017 at the age of 71.

Footnotes

  • ICA
    islet cell autoantibody
    T1D
    type 1 diabetes
    T2D
    type 2 diabetes.

  • Copyright © 2017 by The American Association of Immunologists, Inc.

References

  1. ↵
    1. Karamanou, M.,
    2. A. Protogerou,
    3. G. Tsoucalas,
    4. G. Androutsos,
    5. E. Poulakou-Rebelakou
    . 2016. Milestones in the history of diabetes mellitus: the main contributors. World J. Diabetes 7: 1–7.
    OpenUrl
  2. ↵
    1. Banting, F. G.,
    2. C. H. Best,
    3. J. B. Collip,
    4. W. R. Campbell,
    5. A. A. Fletcher
    . 1922. Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 12: 141–146.
    OpenUrlPubMed
  3. ↵
    1. Himsworth, H. P.
    1936. Management of diabetes mellitus. BMJ 2: 188–190.
    OpenUrlFREE Full Text
  4. ↵
    1. National Diabetes Data Group
    . 1979. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039–1057.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. World Health Organization
    . 1985. Diabetes mellitus. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. 727: 1–113.
    OpenUrlPubMed
  6. ↵
    1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
    . 1997. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183–1197.
    OpenUrlFREE Full Text
  7. ↵
    1. Bottazzo, G. F.,
    2. A. Florin-Christensen,
    3. D. Doniach
    . 1974. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2: 1279–1283.
    OpenUrlPubMed
  8. ↵
    1. MacCuish, A. C.,
    2. W. J. Irvine,
    3. E. W. Barnes,
    4. L. J. Duncan
    . 1974. Antibodies to pancreatic islet cells in insulin-dependent diabetics with coexistent autoimmune disease. Lancet 2: 1529–1531.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Anderson, M. S.,
    2. E. S. Venanzi,
    3. L. Klein,
    4. Z. Chen,
    5. S. P. Berzins,
    6. S. J. Turley,
    7. H. von Boehmer,
    8. R. Bronson,
    9. A. Dierich,
    10. C. Benoist,
    11. D. Mathis
    . 2002. Projection of an immunological self shadow within the thymus by the aire protein. Science 298: 1395–1401.
    OpenUrlAbstract/FREE Full Text
    1. Oftedal, B. E.,
    2. A. Hellesen,
    3. M. M. Erichsen,
    4. E. Bratland,
    5. A. Vardi,
    6. J. Perheentupa,
    7. E. H. Kemp,
    8. T. Fiskerstrand,
    9. M. K. Viken,
    10. A. P. Weetman, et al
    . 2015. Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity 42: 1185–1196.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Anderson, M. S.,
    2. J. L. Casanova
    . 2015. More than meets the eye: monogenic autoimmunity strikes again. Immunity 42: 986–988.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Meyer, S.,
    2. M. Woodward,
    3. C. Hertel,
    4. P. Vlaicu,
    5. Y. Haque,
    6. J. Kärner,
    7. A. Macagno,
    8. S. C. Onuoha,
    9. D. Fishman,
    10. H. Peterson, et al
    . 2016. AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies. Cell 166: 582–595.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Katsarou, A.,
    2. S. Gudbjornsdottir,
    3. A. Rawshani,
    4. D. Dabelea,
    5. E. Bonifacio,
    6. B. J. Anderson,
    7. L. M. Jacobsen,
    8. D. A. Schatz,
    9. A. Lernmark
    . 2017. Type 1 diabetes mellitus. Nat. Rev. Dis. Primers. 3: 17016.
    OpenUrl
  13. ↵
    1. Valle, A.,
    2. G. M. Giamporcaro,
    3. M. Scavini,
    4. A. Stabilini,
    5. P. Grogan,
    6. E. Bianconi,
    7. G. Sebastiani,
    8. M. Masini,
    9. N. Maugeri,
    10. L. Porretti, et al
    . 2013. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 62: 2072–2077.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Yang, M.,
    2. B. Charlton,
    3. A. M. Gautam
    . 1997. Development of insulitis and diabetes in B cell-deficient NOD mice. J. Autoimmun. 10: 257–260.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Martin, S.,
    2. D. Wolf-Eichbaum,
    3. G. Duinkerken,
    4. W. A. Scherbaum,
    5. H. Kolb,
    6. J. G. Noordzij,
    7. B. O. Roep
    . 2001. Development of type 1 diabetes despite severe hereditary B-cell deficiency. N. Engl. J. Med. 345: 1036–1040.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Hinman, R. M.,
    2. M. J. Smith,
    3. J. C. Cambier
    . 2014. B cells and type 1 diabetes ...in mice and men. Immunol. Lett. 160: 128–132.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Hulbert, C.,
    2. B. Riseili,
    3. M. Rojas,
    4. J. W. Thomas
    . 2001. B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J. Immunol. 167: 5535–5538.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Pescovitz, M. D.,
    2. C. J. Greenbaum,
    3. H. Krause-Steinrauf,
    4. D. J. Becker,
    5. S. E. Gitelman,
    6. R. Goland,
    7. P. A. Gottlieb,
    8. J. B. Marks,
    9. P. F. McGee,
    10. A. M. Moran, et al
    . 2009. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361: 2143–2152.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Stiller, C. R.,
    2. A. Laupacis,
    3. J. Dupre,
    4. M. R. Jenner,
    5. P. A. Keown,
    6. W. Rodger,
    7. B. M. Wolfe
    . 1983. Cyclosporine for treatment of early type I diabetes: preliminary results. N. Engl. J. Med. 308: 1226–1227.
    OpenUrlPubMed
    1. Stiller, C. R.,
    2. J. Dupré,
    3. M. Gent,
    4. M. R. Jenner,
    5. P. A. Keown,
    6. A. Laupacis,
    7. R. Martell,
    8. N. W. Rodger,
    9. B. von Graffenried,
    10. B. M. Wolfe
    . 1984. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223: 1362–1367.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Assan, R.,
    2. G. Feutren,
    3. M. Debray-Sachs,
    4. M. C. Quiniou-Debrie,
    5. C. Laborie,
    6. G. Thomas,
    7. L. Chatenoud,
    8. J. F. Bach
    . 1985. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1: 67–71.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Lord, S.,
    2. C. J. Greenbaum
    . 2015. Disease modifying therapies in type 1 diabetes: where have we been, and where are we going? Pharmacol. Res. 98: 3–8.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Orban, T.,
    2. B. Bundy,
    3. D. J. Becker,
    4. L. A. DiMeglio,
    5. S. E. Gitelman,
    6. R. Goland,
    7. P. A. Gottlieb,
    8. C. J. Greenbaum,
    9. J. B. Marks,
    10. R. Monzavi, et al
    . 2011. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378: 412–419.
    OpenUrlCrossRefPubMed
    1. Herold, K. C.,
    2. S. E. Gitelman,
    3. M. R. Ehlers,
    4. P. A. Gottlieb,
    5. C. J. Greenbaum,
    6. W. Hagopian,
    7. K. D. Boyle,
    8. L. Keyes-Elstein,
    9. S. Aggarwal,
    10. D. Phippard, et al
    . 2013. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62: 3766–3774.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Rigby, M. R.,
    2. K. M. Harris,
    3. A. Pinckney,
    4. L. A. DiMeglio,
    5. M. S. Rendell,
    6. E. I. Felner,
    7. J. M. Dostou,
    8. S. E. Gitelman,
    9. K. J. Griffin,
    10. E. Tsalikian, et al
    . 2015. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J. Clin. Invest. 125: 3285–3296.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Palmer, J. P.,
    2. C. M. Asplin,
    3. P. Clemons,
    4. K. Lyen,
    5. O. Tatpati,
    6. P. K. Raghu,
    7. T. L. Paquette
    . 1983. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222: 1337–1339.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Baekkeskov, S.,
    2. H. J. Aanstoot,
    3. S. Christgau,
    4. A. Reetz,
    5. M. Solimena,
    6. M. Cascalho,
    7. F. Folli,
    8. H. Richter-Olesen,
    9. P. De Camilli
    . 1990. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. [Published erratum appears in 1990 Nature 347: 782.] Nature 347: 151–156.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Bonifacio, E.,
    2. V. Lampasona,
    3. S. Genovese,
    4. M. Ferrari,
    5. E. Bosi
    . 1995. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J. Immunol. 155: 5419–5426.
    OpenUrlAbstract
  27. ↵
    1. Wenzlau, J. M.,
    2. K. Juhl,
    3. L. Yu,
    4. O. Moua,
    5. S. A. Sarkar,
    6. P. Gottlieb,
    7. M. Rewers,
    8. G. S. Eisenbarth,
    9. J. Jensen,
    10. H. W. Davidson,
    11. J. C. Hutton
    . 2007. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. USA 104: 17040–17045.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Delong, T.,
    2. T. A. Wiles,
    3. R. L. Baker,
    4. B. Bradley,
    5. G. Barbour,
    6. R. Reisdorph,
    7. M. Armstrong,
    8. R. L. Powell,
    9. N. Reisdorph,
    10. N. Kumar, et al
    . 2016. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351: 711–714.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Jin, N.,
    2. Y. Wang,
    3. F. Crawford,
    4. J. White,
    5. P. Marrack,
    6. S. Dai,
    7. J. W. Kappler
    . 2015. N-terminal additions to the WE14 peptide of chromogranin A create strong autoantigen agonists in type 1 diabetes. Proc. Natl. Acad. Sci. USA 112: 13318–13323.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. McGinty, J. W.,
    2. I. T. Chow,
    3. C. Greenbaum,
    4. J. Odegard,
    5. W. W. Kwok,
    6. E. A. James
    . 2014. Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. Diabetes 63: 3033–3040.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Insel, R. A.,
    2. J. L. Dunne,
    3. M. A. Atkinson,
    4. J. L. Chiang,
    5. D. Dabelea,
    6. P. A. Gottlieb,
    7. C. J. Greenbaum,
    8. K. C. Herold,
    9. J. P. Krischer,
    10. Å. Lernmark, et al
    . 2015. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American diabetes association. Diabetes Care 38: 1964–1974.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Battaglia, M.,
    2. M. S. Anderson,
    3. J. H. Buckner,
    4. S. M. Geyer,
    5. P. A. Gottlieb,
    6. T. W. H. Kay,
    7. Å. Lernmark,
    8. S. Muller,
    9. A. Pugliese,
    10. B. O. Roep, et al
    . 2017. Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. DOI: 10.1007/s00125-017-4384-2.
PreviousNext
Back to top

In this issue

The Journal of Immunology: 199 (9)
The Journal of Immunology
Vol. 199, Issue 9
1 Nov 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease
Jane H. Buckner, Carla J. Greenbaum
The Journal of Immunology November 1, 2017, 199 (9) 3011-3013; DOI: 10.4049/jimmunol.1701299

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease
Jane H. Buckner, Carla J. Greenbaum
The Journal of Immunology November 1, 2017, 199 (9) 3011-3013; DOI: 10.4049/jimmunol.1701299
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Conceiving the Inconceivable: The Function of Aire in Immune Tolerance to Peripheral Tissue-Restricted Antigens in the Thymus
  • Glial Cells as Regulators of Neuroimmune Interactions in the Central Nervous System
  • The Colon as a Major Site of Immunoregulation by CD4+ T Cell Subsets in the Steady State
Show more PILLARS OF IMMUNOLOGY

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606